薄芝糖肽临床应用中文文献分析

发布时间：2018-05-22 15:51

本文选题：薄芝糖肽 + 临床应用　；参考：《中国药师》2016年06期

【摘要】：目的:分析薄芝糖肽临床应用情况,为临床合理用药提供参考。方法:检索相关期刊论文(CNKI)、万方数据库、维普资讯网(VIP)收录的薄芝糖肽相关文献,对薄芝糖肽主要临床应用(同病种文献发表数量大于3篇)及不良反应进行统计和分析。结果:检索得文献163篇,包含临床应用文献137篇,其中文献发表数大于3篇的病种有尖锐湿疣(9篇)、带状疱疹(6篇)、手足口病(6篇)、寻常型银屑病(6篇)、肺癌(5篇)、小儿反复呼吸道感染(4篇)、乙型肝炎(9篇),共计45篇。45篇临床应用文献中有32篇(共1 772例)涉及不良反应病例,有49例发生不良反应,发生率为2.77%,以皮肤及其附件损害为主(10例,20.0%)。ADR病例报道11篇,涉及病例数20例,以寒战和发热为主(13例,37.2%)。结论:薄芝糖肽作为辅助用药在临床上主要与其他药物联合应用,能够增强主要治疗药物的疗效,不良反应发生率低且以皮肤及其附件损害为主。
[Abstract]:Objective: to analyze the clinical application of Ganoderma lucidum glycopeptide in order to provide reference for rational drug use. Methods: to search the related documents of Ganoderma lucidum glycopeptide included in CNKI, Wanfang database, Weipu Web site and VIPs. The main clinical application of Glucoderma lucidum glycopeptide (more than 3 articles published in the same disease literature) and adverse reactions were analyzed. Results: 163 articles were retrieved, including 137 articles of clinical application. Among them, more than 3 articles were published on the following diseases: condyloma acuminatum (9), herpes zoster (6), hand, foot and mouth (6), psoriasis vulgaris (6), lung cancer (5), recurrent respiratory tract infection in children (4), hepatitis B (9). Among 45 articles of clinical application, 32 (1 772 cases) involved adverse reactions. There were 49 cases of adverse reactions (2.77%), 10 cases were mainly skin and adnexal lesions, 11 cases were reported, 20 cases were involved, 13 cases were chills and fever. Conclusion: Ganoderma lucidum glycopeptide as an adjuvant drug can be combined with other drugs in clinic, which can enhance the efficacy of the main therapeutic drugs. The incidence of adverse reactions is low and the damage to skin and its appendages is the main adverse reaction.
【作者单位】：山西医科大学药学院;山西医科大学第一医院药剂科;
【分类号】：R977

【相似文献】